Repligen (NASDAQ:RGEN) Shares Gap Up – Still a Buy?

Shares of Repligen Co. (NASDAQ:RGEN) gapped up before the market opened on Tuesday . The stock had previously closed at $168.01, but opened at $176.29. Repligen shares last traded at $172.44, with a volume of 272,942 shares trading hands.

Analysts Set New Price Targets

A number of research firms recently commented on RGEN. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. HC Wainwright decreased their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $184.73.

Repligen Stock Performance

The firm has a market capitalization of $9.69 billion, a price-to-earnings ratio of -467.41, a price-to-earnings-growth ratio of 4.51 and a beta of 0.97. The firm’s 50-day moving average price is $150.83 and its two-hundred day moving average price is $146.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period last year, the business earned $0.23 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. Sell-side analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Institutional Trading of Repligen

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Repligen by 46.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company’s stock worth $2,679,000 after acquiring an additional 5,913 shares in the last quarter. Alliance Wealth Advisors LLC UT raised its position in Repligen by 5.9% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 3,586 shares of the biotechnology company’s stock valued at $516,000 after purchasing an additional 199 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after purchasing an additional 6,872 shares in the last quarter. Slow Capital Inc. grew its holdings in shares of Repligen by 3.3% during the fourth quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 534 shares during the last quarter. Finally, Ballentine Partners LLC increased its stake in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.